Speaker Profile
Dale N. Gerding

Dale N. Gerding MD, MACP, FIDSA, FSHEA

Infectious Disease
Hines, Illinois, United States of America

Connect with the speaker?

Dr. Dale N. Gerding, MD, MACP, FIDSA, FSHEA, is a Research Physician at the Edward Hines Jr. VA Hospital, USA. He is a Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois (retired). Prior to his present position, Dr. Gerding was Chief of Medicine at VA Chicago, Lakeside Division, and Professor of Medicine at Northwestern University Feinberg School of Medicine. He is an infectious diseases specialist and hospital epidemiologist, past president of the Society for Healthcare Epidemiology of America, and past chair of the antibiotic resistance committee of SHEA. He is a fellow of the Infectious Diseases Society of America (IDSA) and past Chair of the National and Global Public Health Committee, the Antibiotic Resistance Subcommittee, and is co-chair of the guideline for Clostridium difficile infection of IDSA and SHEA. He served as a member of the Board of Directors of IDSA from 2005-2008. He has been honored with the Lifetime Achievement award of the Anaerobe Society of the Americas in 2010 where he is also a past president. He has also received the Lifetime Achievement Award of the Veterans Affairs Society for Physicians in Infectious Disease in 2014. He is a Master of the American College of Physicians and the 2013 recipient of the William Middleton Award, the highest research award given by the Department of Veterans Affairs. He is a member of the American Society for Microbiology and is board certified in Internal Medicine and Infectious Diseases.

His research interests include the epidemiology and prevention of CDI, antimicrobial resistance, and antimicrobial distribution and kinetics. He has been a Merit Review funded research investigator in the VA for over 40 years and is the author of over 400 peer-reviewed journal publications, book chapters, and review articles. He holds patents and technology for the use of non-toxigenic C. difficile for the prevention and treatment of this disease. He is a member of the editorial boards of Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy, Gut Microbes, and Infection Control and Hospital Epidemiology, and is a reviewer for numerous other medical journals.
EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)